ArticleLeukemia2021

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

David P Steensma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.